Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-Label, Single-Arm Study to Evaluate Long-Term Safety, Tolerability, and Effectiveness of 10 mg/kg BID Olesoxime in Patients With Spinal Muscular Atrophy

NCT02628743 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02628743
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02628743 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-Label, Single-Arm Study to Evaluate Long-Term Safety, Tolerability, and Effectiveness of 10 mg/kg BID Olesoxime in Patients With Spinal Muscular Atrophy
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
January 20, 2016
Completion date
December 18, 2018
Enrollment
131 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

muscular atrophy, spinal